Evotec (NASDAQ:EVO) SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.
Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design. Its proprietary technologies and automation solutions are engineered to streamline early-stage research, reduce timelines and costs, and improve the probability of success for small molecules, biologics, and cell therapies.
Founded in 1993, Evotec has expanded its capabilities through strategic collaborations, acquisitions, and the growth of its global R&D infrastructure. The company maintains research sites across Europe, North America, and Asia, providing clients with access to diverse scientific expertise and regional innovation hubs in major life sciences clusters.
Evotec’s leadership team brings together seasoned executives from the biotechnology and pharmaceutical industries, guiding a strategic focus on both fee-for-service engagements and milestone-based alliances. Under this direction, Evotec continues to evolve as an integrated drug discovery powerhouse, advancing its own proprietary pipeline alongside its partnership-driven business model.
